Related Experiment Video
Updated: Nov 20, 2025
10:37
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
8.5K
Irritable Bowel Syndrome in Pregnancy
Sarvee Moosavi1, Mark Pimentel2,3,4, Melissa S Wong5
1Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
The American Journal of Gastroenterology
|January 22, 2021
Summary
Irritable bowel syndrome (IBS) in pregnant women is understudied. This review covers IBS effects during pregnancy, management strategies, and safe treatment options for expectant mothers.
Area of Science:
- Gastroenterology and Obstetrics
Background:
- Irritable bowel syndrome (IBS) is prevalent, particularly in women of childbearing age.
- Limited research exists on IBS epidemiology, prognosis, and management during pregnancy.
- This knowledge gap challenges healthcare providers in managing pregnant IBS patients.
Purpose of the Study:
- To review current literature on the effects of pregnancy on IBS and vice versa.
- To assess the efficacy and safety of common IBS treatments in pregnancy.
- To identify knowledge gaps and guide management strategies for pregnant IBS patients.
Main Methods:
- Comprehensive literature review of studies on IBS and pregnancy.
- Analysis of existing data on IBS management during gestation.
- Evaluation of safety and efficacy profiles for IBS diets and medications in pregnancy.
Main Results:
- Pregnancy can alter IBS symptoms, and IBS may impact pregnancy outcomes, though data is scarce.
- Many commonly used IBS treatments lack established safety profiles for pregnancy.
- Multidisciplinary management, education, and cautious use of safe interventions are key.
Conclusions:
- There is a critical need for more research on IBS in pregnancy.
- Healthcare providers should adopt a multidisciplinary approach for pregnant IBS patients.
- Prioritize patient education and the judicious use of safe dietary and pharmacologic interventions.
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
673
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
673
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
488
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
488
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
513
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
513
01:17Drugs for Treatment of Diarrhea-Predominant IBS
431
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
431
01:21Drugs for Treatment of Constipation-Predominant IBS
483
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
483
01:17Chronic Bowel Disorders: Introduction
635
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
635